Enyo Pharma

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Farnesoid X receptor (FXR/NR1H4)Small molecule
Chronic Kidney DiseaseMASH / NASH

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 January 2026Topline resultVonafexorPhase 2 ALPESTRIA-1 of vonafexor in Alport syndrome: topline results
Enyo Pharma · Source ↗

Financial reports

No financial reports recorded.